All articles tagged with #opdivo
Bristol Myers Squibb beat expectations on second-quarter adjusted earnings and revenue and lifted its full-year guidance to $49–$50 billion as newer therapies offset declines in legacy drugs; Eliquis grew 21% to $4.48 billion, contributing to the beat and helping lift the stock.
The European Society for Medical Oncology (ESMO) Congress 2023 has experienced an embargo breach, revealing promising therapies for non-small cell lung cancer (NSCLC). Bristol Myers Squibb's Opdivo demonstrated positive results in two Phase III studies, showing a reduction in disease recurrence and improved survival rates. Mirati's adagrasib, when combined with Keytruda, showed strong first-line promise in NSCLC patients. BeiGene's tislelizumab, in combination with chemotherapy, achieved a major pathological response in a Phase III trial. Johnson & Johnson's Rybrevant-lazertinib combination demonstrated potential as a new standard of care for EGFR-mutated NSCLC. These findings will be presented at the ESMO Congress in October.
Bristol Myers Squibb has announced positive results from the Phase 3 CheckMate -901 trial, showing that the combination of Opdivo (nivolumab) with cisplatin-based chemotherapy followed by Opdivo monotherapy demonstrated significant benefits in overall survival (OS) and progression-free survival (PFS) compared to standard-of-care cisplatin-based combinations as a first-line treatment for patients with unresectable or metastatic urothelial carcinoma who are eligible for cisplatin-based chemotherapy. This marks the first immunotherapy-based combination to improve both OS and PFS in this patient population, highlighting the potential of Opdivo-based treatments in various genitourinary cancers.